Literature DB >> 12445150

Epidemiology of neonatal group B streptococcal disease in The Netherlands 1997-98.

Monique Trijbels-Smeulders1, Leo J Gerards, Pieternel C M, Pasker de Jong, Richard A van Lingen, Albert H Adriaanse, Guus A de Jonge, Louis A A Kollée.   

Abstract

Group B streptococcal (GBS) infection is still an important cause of morbidity and mortality in newborn infants. In The Netherlands, there are no published data on the incidence of neonatal GBS infection. We collected data of all infants with GBS disease during the first 3 months of life, as reported to the Dutch Paediatric Surveillance Unit (DPSU) during a period of 2 years (1997-98). Neonates with early-onset GBS disease (both sepsis and probable sepsis) were included for further analysis. The level of completeness of the DPSU data was determined by capture-recapture techniques. The incidence of early-onset GBS disease in The Netherlands in 1997-98, as calculated from the DPSU data, was 0.9 per 1000 live births. After correction for under-reporting, the incidence was estimated to be 1.9 per 1000 live births. The case fatality rate of early-onset GBS disease was only 5%. Despite the decrease in the mortality rate during the last decades, it remains a serious condition with potential irreversible brain damage. Therefore, formal guidelines for the prevention of neonatal early-onset GBS disease in The Netherlands were introduced in 1999. The data collected in this study may serve as baseline data for evaluation of the effect of these guidelines.

Entities:  

Mesh:

Year:  2002        PMID: 12445150     DOI: 10.1046/j.1365-3016.2002.00437.x

Source DB:  PubMed          Journal:  Paediatr Perinat Epidemiol        ISSN: 0269-5022            Impact factor:   3.980


  11 in total

1.  Beyond counting cases: public health impacts of national Paediatric Surveillance Units.

Authors:  D Grenier; E J Elliott; Y Zurynski; R Rodrigues Pereira; M Preece; R Lynn; R von Kries; H Zimmermann; N P Dickson; D Virella
Journal:  Arch Dis Child       Date:  2006-12-11       Impact factor: 3.791

2.  Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection.

Authors:  C Larsson; M Lindroth; P Nordin; M Stålhammar-Carlemalm; G Lindahl; I Krantz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

Review 3.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Phlegmonous gastritis in a 32-week pregnant woman managed by conservative surgical treatment and antibiotics.

Authors:  Séverine Hommel; Guillaume Savoye; Camille Lorenceau-Savale; Bruno Costaglioli; François Baron; Florence Le Pessot; Françoise Lemoine; Eric Lerebours
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

Review 5.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

6.  Barriers and facilitators related to the uptake of four strategies to prevent neonatal early-onset group B haemolytic streptococcus disease: a qualitative study.

Authors:  Diny G E Kolkman; Margot A H Fleuren; Maurice G A J Wouters; Christianne J M de Groot; Marlies E B Rijnders
Journal:  BMC Pregnancy Childbirth       Date:  2017-05-09       Impact factor: 3.007

7.  Genotyping of Streptococcus agalactiae (group B streptococci) isolated from vaginal and rectal swabs of women at 35-37 weeks of pregnancy.

Authors:  Nabil Abdullah El Aila; Inge Tency; Geert Claeys; Bart Saerens; Ellen De Backer; Marleen Temmerman; Rita Verhelst; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2009-09-11       Impact factor: 3.090

8.  Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis.

Authors:  Gary M Ginsberg; Arthur I Eidelman; Eric Shinwell; Emilia Anis; Reuven Peyser; Yoram Lotan
Journal:  Isr J Health Policy Res       Date:  2013-02-20

9.  Implementation of a cost-effective strategy to prevent neonatal early-onset group B haemolytic streptococcus disease in the Netherlands.

Authors:  Diny G E Kolkman; Marlies E B Rijnders; Maurice G A J Wouters; M Elske van den Akker-van Marle; Cpb Kitty van der Ploeg; Christianne J M de Groot; Margot A H Fleuren
Journal:  BMC Pregnancy Childbirth       Date:  2013-07-30       Impact factor: 3.007

10.  Estimating rheumatic fever incidence in New Zealand using multiple data sources.

Authors:  J Oliver; N Pierse; M G Baker
Journal:  Epidemiol Infect       Date:  2014-03-06       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.